Risk stratification of stage II rectal mucinous adenocarcinoma to predict the benefit of adjuvant chemotherapy following neoadjuvant chemoradiation and surgery

Risk stratification of stage II rectal mucinous adenocarcinoma to predict the benefit of adjuvant chemotherapy following neoadjuvant chemoradiation and surgery

BackgroundThe treatment strategy for stage II rectal mucinous adenocarcinoma (RMA) recommends neoadjuvant chemoradiotherapy (NCR) followed by total mesorectal excision (TME). However, the necessity of adjuvant chemotherapy (AC) remains controversial.Materials and methodsChi-square test was used to a...

Full description

Bibliographic Details
Main Authors: Yahang Liang, Hualin Liao, Haoran Shi, Tao Li, Yaxiong Liu, Yuli Yuan, Mingming Li, Aidi Li, Yang Liu, Yao Yao, Taiyuan Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-03-01
Series:Frontiers in Oncology
Subjects:
neoadjuvant chemoradiation
stage II rectal mucinous adenocarcinoma
adjuvant chemotherapy
nomogram
survival
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1352660/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1352660/full

Similar Items